DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
41 hedge funds and large institutions have $3.81M invested in DMK Pharmaceuticals Corporation Common Stock in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 11 closing their positions.
276% more call options, than puts
Call options by funds: $316K | Put options by funds: $84K
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
11% less funds holding
Funds holding: 46 → 41 (-5)
27% less capital invested
Capital invested by funds: $5.18M → $3.81M (-$1.37M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$293K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$37.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$795K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$221K |
| 3 |
VF
Virtu Financial
New York
|
-$31K |
| 4 |
JCM
Jacobi Capital Management
Pittston,
Pennsylvania
|
-$20K |
| 5 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
-$19.1K |
DMK Hedge Fund Activity: Q4 2020 in Review
41 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2020, worth a combined $3.81M — down 27% from $5.18M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of DMK and 6 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 11 added.
The largest buyer was GSA Capital Partners, adding an estimated $293K. The largest seller was Maven Securities, exiting entirely with an estimated $795K sold.
- 41 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2020, down from 46 in Q3 2020.
- Funds reported $3.81M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2020, down 27% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2020 and 11 closed out, a net change of -5 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2020 was GSA Capital Partners, an estimated $293K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2020 was Maven Securities, an estimated $795K sold.
Based on aggregated 13F filings for Q4 2020.